Baker Bros. Advisors LP Candel Therapeutics, Inc. Transaction History
Baker Bros. Advisors LP
- $9.02 Billion
- Q4 2024
A detailed history of Baker Bros. Advisors LP transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 2,981,983 shares of CADL stock, worth $27 Million. This represents 0.29% of its overall portfolio holdings.
Number of Shares
2,981,983Holding current value
$27 Million% of portfolio
0.29%Shares
1 transactions
Others Institutions Holding CADL
# of Institutions
71Shares Held
10.7MCall Options Held
750KPut Options Held
469K-
Acorn Capital Advisors, LLC New York, NY1.94MShares$17.6 Million9.1% of portfolio
-
Northpond Ventures, LLC1.94MShares$17.5 Million48.35% of portfolio
-
Braidwell LP Stamford, CT1.6MShares$14.5 Million0.78% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.34MShares$12.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY823KShares$7.45 Million0.0% of portfolio
About Candel Therapeutics, Inc.
- Ticker CADL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,891,900
- Market Cap $261M
- Description
- Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...